ArticleTranslational vision science & technology2025
VascX Models: Deep Ensembles for Retinal Vascular Analysis From Color Fundus Images.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Retinalysis-Vascx: An Explainable Software Toolbox for the Extraction of Retinal Vascular Biomarkers From Color Fundus Images.Translational vision science & technology · 2026Article
- Deep learning aging marker from retinal images unveils sex-specific clinical and genetic signatures.Nature communications · 2026Article
- Factors Associated with Machine Learning-Based Predictions of Retinal Aging Using Teleretinal Screening Images from Patients with Diabetes.Ophthalmology science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To present and validate deep learning model ensembles (VascX) for vessel, artery-vein, optic disc segmentation, and fovea localization for color fundus images (CFIs). VascX preprocessing and inference code and model weights were made publicly available to facilitate research on retinal vasculature. Methods: For model training, we combined over 15 published annotated datasets with CFIs from Dutch studies (mainly the Rotterdam Study). This resulted in diverse development sets with a variety of patient characteristics and imaging conditions. We trained UNet model ensembles using a new, more robust preprocessing algorithm and strong data augmentations. We compared VascX segmentation performance (Dice) to models with publicly available weights: AutoMorph and LittleWNet. We compared the quality of VascX (and previous models') features by measuring agreement (mean absolute error [MAE] and Pearson correlation) with features extracted from grader segmentations. Results: Dice scores revealed better performance from VascX across most datasets evaluated, especially for artery-vein and optic disc segmentation. VascX performed more consistently as the quality of the images decreased and for both disc and fovea-centered images. These improvements translated into higher-quality vascular features. Of 24 features evaluated, 14 showed a significant improvement in MAE when compared to AutoMorph and 23 when compared to LWNet. VascX had the highest correlations with ground-truth features in all but two cases. Conclusions: VascX models perform well across a variety of conditions, likely due to the size and diversity of our development sets. VascX represents an important improvement in segmentation quality that translates into better vascular features to support more robust analyses of the retinal vasculature. Translational Relevance: By making VascX public, we aim to facilitate and improve research linking retinal vascular biomarkers to ophthalmic and systemic conditions, relevant for the detection, prevention, and monitoring of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.